CASI Pharmaceuticals, headquartered in Beijing, focuses on developing and commercializing therapeutics, with a particular emphasis on hematology oncology and other medical needs worldwide. The company, which went public in 2021, markets products like EVOMELA in the U.S. and has several pipeline products and FDA-approved generics for the China market.
3 analysts think CASI stock price will increase by 66.98%. The current median analyst target is $6.12 compared to a current stock price of $3.67. The lowest analysts target is $6.06 and the highest analyst target is $6.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
